BOSTON, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that the company will participate in two upcoming investor conferences. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry. President and Chief Medical Officer, Evan Loh, MD, will present at the following events:
- Baird’s 2016 Global Healthcare Conference on Wednesday, September 7 from 1:25 to 1:55 p.m. at the New York Palace Hotel. To access the live webcast of Paratek's Baird presentation, please visit http://wsw.com/webcast/baird46/prtk. A replay of the webcast can be accessed for up to 90 days following the live presentation.
- Ladenburg Thalmann 2nd Annual Healthcare Conference on Tuesday, September 27 from 10:30 to 10:55 a.m. at the Sofitel New York. To access the live webcast of Paratek's Ladenburg Thalmann presentation, please visit http://wsw.com/webcast/ladenburg2/prtk. A replay of the webcast can be accessed for up to 90 days following the live presentation.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. In June 2016 Paratek announced positive efficacy data in a Phase 3 registration study in ABSSSI demonstrating the efficacy and safety of omadacycline compared to linezolid. A Phase 3 registration study for community acquired bacterial pneumonia (CABP) comparing IV to oral omadacycline to IV to oral moxifloxacin was initiated in November 2015. Enrollment continues on track to report top line data, which are expected as early as the third quarter of 2017. A Phase 3 registration study in ABSSSI comparing once-daily oral only dosing of omadacycline to twice-daily oral-only dosing of linezolid was initiated in August 2016. Top line data are expected as early as the second quarter of 2017. A phase 1b study in uncomplicated urinary tract infections (UTI) was initiated in May 2016. Enrollment is nearly complete with top line data expected as early as the fourth quarter of 2016. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration.
Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.
Paratek's second Phase 3 product candidate, sarecycline, is designed to be a well-tolerated, once-daily, oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan initiated two identical Phase 3 registration studies in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris. Top line data are expected in the first half of 2017. For more information, visit www.paratekpharma.com.
For more information, visit www.paratekpharma.com.
CONTACTS: Media Relations: Michael Lampe (484) 575-5040 email@example.com Investor Relations: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568